|
WO2021062282A1
|
|
Combination therapy with cgrp antagonists
|
|
WO2021037733A1
|
|
Tropoelastin for use in treatment of acne scarring
|
|
WO2021005493A1
|
|
Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
|
|
WO2021005497A1
|
|
Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
|
|
WO2021005494A1
|
|
Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
|
|
US2020345623A1
|
|
Methods of scar prevention and/or treatment
|
|
TW202019459A
|
|
Combination therapy with cgrp antagonists and clostridial derivatives
|
|
US2019374520A1
|
|
Treatment of migraine
|
|
US2019374518A1
|
|
Treatment of migraine
|
|
US2019275087A1
|
|
Expansion and differentiation of stem cells
|
|
CN111343991A
|
|
Treatment of non-inflammatory lesions
|
|
EP3534982A1
|
|
Biosynthetic devices
|
|
US2018243381A1
|
|
Formation of bone
|
|
CN111840246A
|
|
Formulations and methods for vaginal delivery of antiprogestins
|
|
MX2016000794A
|
|
High potency pancreatin pharmaceutical compositions.
|
|
AU2013267359A1
|
|
Formulations and methods for vaginal delivery of antiprogestins
|
|
AU2011218625A1
|
|
Dosage forms of risedronate
|
|
AU2010223851A1
|
|
Injectable biomaterials
|
|
EP3470055A1
|
|
Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs
|
